Lifecore Biomedical Inc. (LFCR) - Cash Flow Conversion Efficiency

Latest as of May 2026: -0.136x

Based on the latest financial reports, Lifecore Biomedical Inc. (LFCR) has a cash flow conversion efficiency ratio of -0.136x as of May 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.19 Million) by net assets ($16.09 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of Lifecore Biomedical Inc. for the company's overall valuation and market capitalisation.

Lifecore Biomedical Inc. - Cash Flow Conversion Efficiency Trend (1996–2026)

This chart illustrates how Lifecore Biomedical Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.

Lifecore Biomedical Inc. Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Lifecore Biomedical Inc. ranked by their cash flow conversion efficiency. Explore Lifecore Biomedical Inc. earnings quality ratio to measure how well operating cash flow supports reported net income.

Company Cash Flow Conversion Efficiency
Daeho Al Co. Ltd.
KO:069460
0.081x
Sparebanken Ost
OL:SPOG
0.022x
1911 Gold Corp
V:AUMB
-0.121x
Scottie Resources Corp
V:SCOT
-1.010x
Sang-A Frontec Co.Ltd
KQ:089980
0.080x
Valens
NYSE:VLN
-0.043x
Jyong Biotech Ltd. Ordinary Shares
NASDAQ:MENS
0.037x
Tianjin Capital Environmental Protection Group Company Limited
F:TIA
0.070x

Annual Cash Flow Conversion Efficiency for Lifecore Biomedical Inc. (1996–2026)

The table below shows the annual cash flow conversion efficiency of Lifecore Biomedical Inc. from 1996 to 2026. View Lifecore Biomedical Inc. share price for real-time trading data and today's change.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2026-05-31 $-14.20 Million $12.57 Million -0.885x -473.82%
2025-05-31 $1.34 Million $-206.00K -0.154x -778.86%
2024-05-31 $11.31 Million $257.00K 0.023x +108.83%
2023-05-31 $87.82 Million $-22.59 Million -0.257x -13.81%
2022-05-31 $107.94 Million $-24.40 Million -0.226x -378.28%
2021-05-31 $202.78 Million $16.47 Million 0.081x +210.12%
2020-05-31 $231.04 Million $-17.04 Million -0.074x -224.38%
2019-05-31 $270.14 Million $16.02 Million 0.059x -24.28%
2018-05-31 $252.56 Million $19.78 Million 0.078x -39.08%
2017-05-31 $228.15 Million $29.33 Million 0.129x +25.30%
2016-05-31 $212.35 Million $21.78 Million 0.103x -13.67%
2015-05-31 $220.11 Million $26.16 Million 0.119x +15.62%
2014-05-31 $204.76 Million $21.05 Million 0.103x -12.66%
2013-05-31 $180.41 Million $21.23 Million 0.118x -19.60%
2012-05-31 $151.56 Million $22.18 Million 0.146x +39.31%
2011-05-31 $137.73 Million $14.47 Million 0.105x +85.99%
2010-05-31 $132.47 Million $7.48 Million 0.056x -23.85%
2009-05-31 $127.20 Million $9.44 Million 0.074x -50.88%
2008-05-31 $116.02 Million $17.52 Million 0.151x +920.78%
2007-05-31 $112.07 Million $-2.06 Million -0.018x -114.70%
2006-05-31 $86.82 Million $10.87 Million 0.125x -29.48%
2005-05-31 $73.53 Million $13.05 Million 0.177x +41.16%
2004-05-31 $63.10 Million $7.93 Million 0.126x +7262.63%
2002-05-31 $57.54 Million $-101.00K -0.002x +98.82%
2001-05-31 $50.87 Million $-7.57 Million -0.149x -269.33%
2000-05-31 $57.00 Million $5.01 Million 0.088x +177.61%
1999-05-31 $31.80 Million $-3.60 Million -0.113x -12.21%
1998-05-31 $33.70 Million $-3.40 Million -0.101x +34.70%
1997-05-31 $35.60 Million $-5.50 Million -0.154x -57.07%
1996-05-31 $36.60 Million $-3.60 Million -0.098x --

About Lifecore Biomedical Inc.

NASDAQ:LFCR USA Drug Manufacturers - Specialty & Generic
Market Cap
$156.71 Million
Market Cap Rank
#17550 Global
#4151 in USA
Share Price
$4.14
Change (1 day)
-2.59%
52-Week Range
$3.66 - $8.82
All Time High
$15.45
About

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device … Read more